In vitro assessment of metabolic drug–drug interaction potential of AZD2624, neurokinin-3 receptor antagonist, through cytochrome P₄₅₀ enzyme identification, inhibition, and induction studies

References

• Almeida TA, Rojo J, Nieto PM, Pinto FM, Hernandez M, Martín JD, Candenas ML. (2004). Tachykinins and tachykinin receptors: structure and activity relationships. Curr Med Chem 11:2045–2081.
   PubMed Web of Science ®Google Scholar
• Chen Y, Ferguson SS, Negishi M, Goldstein JA. (2004). Induction of human CYP2C9 by rifampicin, hyperforin, and phenobarbital is mediated by the pregnane X receptor. J Pharmacol Exp Ther 308, 495–501.
   PubMed Web of Science ®Google Scholar
• Dawson LA, Smith PW. (2010). Therapeutic utility of NK3 receptor antagonists for the treatment of schizophrenia. Curr Pharm Des 16:344–357.
   PubMed Web of Science ®Google Scholar
• Denison MS, Nagy SR. (2003). Activation of the aryl hydrocarbon receptor by structurally diverse exogenous and endogenous chemicals. Annu Rev Pharmacol Toxicol 43:309–334.
   PubMed Web of Science ®Google Scholar
• Evangelista S. (2005). Talnetant GlaxoSmithKline. Curr Opin Investig Drugs 6:717–721.
   PubMedGoogle Scholar
• Gerard NP, Bao L, Xiao-Ping H, Gerard C. (1993). Molecular aspects of the tachykinin receptors. Regul Pept 43:21–35.
   PubMed Web of Science ®Google Scholar
• Gibson GG, Plant NJ, Swales KE, Ayrton A, El-Sankary W. (2002). Receptor-dependent transcriptional activation of cytochrome P4503A genes: induction mechanisms, species differences and interindividual variation in man. Xenobiotica 32:165–206.
   PubMed Web of Science ®Google Scholar
• Guengerich FP. (1999). Cytochrome P-450 3A4: regulation and role in drug metabolism. Annu Rev Pharmacol Toxicol 39:1–17.
   PubMed Web of Science ®Google Scholar
• Hewitt NJ, Lecluyse EL, Ferguson SS. (2007). Induction of hepatic cytochrome P450 enzymes: methods, mechanisms, recommendations, and in vitro-in vivo correlations. Xenobiotica 37:1196–1224.
   PubMed Web of Science ®Google Scholar
• Kuehl P, Zhang J, Lin Y, Lamba J, Assem M, Schuetz J, Watkins PB, Daly A, Wrighton SA, Hall SD, Maurel P, Relling M, Brimer C, Yasuda K, Venkataramanan R, Strom S, Thummel K, Boguski MS, Schuetz E. (2001). Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet 27:383–391.
   PubMed Web of Science ®Google Scholar
• Langlois X, Wintmolders C, te Riele P, Leysen JE, Jurzak M. (2001). Detailed distribution of Neurokinin 3 receptors in the rat, guinea pig and gerbil brain: a comparative autoradiographic study. Neuropharmacology 40:242–253.
   PubMed Web of Science ®Google Scholar
• LeCluyse EL. (2001). Human hepatocyte culture systems for the in vitro evaluation of cytochrome P450 expression and regulation. Eur J Pharm Sci 13:343–368.
   PubMed Web of Science ®Google Scholar
• Li XQ, Andersson TB, Ahlström M, Weidolf L. (2004). Comparison of inhibitory effects of the proton pump-inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole on human cytochrome P450 activities. Drug Metab Dispos 32:821–827.
   PubMed Web of Science ®Google Scholar
• Maggi CA. (1995). The mammalian tachykinin receptors. Gen Pharmacol 26:911–944.
   PubMedGoogle Scholar
• Meltzer HY, Arvanitis L, Bauer D, Rein W; Meta-Trial Study Group. (2004). Placebo-controlled evaluation of four novel compounds for the treatment of schizophrenia and schizoaffective disorder. Am J Psychiatry 161:975–984.
   PubMed Web of Science ®Google Scholar
• Nakanishi S. (1991). Mammalian tachykinin receptors. Annu Rev Neurosci 14:123–136.
   PubMed Web of Science ®Google Scholar
• Simpson TR, Kang J, Albert JS, Alhambra C, Koether GM, Woods JM, Li Y. (2007). Preparation of quinoline derivatives as neurokinin-3 receptor antagonists. PCT Int Appl 48pp WO2007069977.
   Google Scholar
• Simpson TR, Gadient R, Li Y, Kanes S, Lengel D, Potts W, Yang W, Kang J, Woods JM, Alhambra C, Albert JS, Koether GM, Do ML, Scott C, Sobotka-Briner C, Maier D, Medd A, Mrzljak L, Defay T, Furlong S, Mathisen D, Sygowski L, Williams A, Condon S, Wilkins D, Bi V, Morelli J, Otieno M, Kelsall J, Smith M, Stong D, Desai D, Tollemar U, Keith R, Boss A, Davis P, Sloan A, Zhou D, Pierson E, Cantagallo K, Litman R, Gertsik LG, Dragan Y, Simpson B, Eisman M, Xiao A, Litwin LC, Sweitzer DE, Wang Y, Ennis DJ, Garber S, Rak IW. (2010). Discovery of AZD2624: A potent and selective NK3 antagonist to test the NK3 hypothesis in schizophrenia. 239th ACS National Meeting, San Francisco, CA, United States, March 21–25, MEDI-35.
   Google Scholar
• Spooren W, Riemer C, Meltzer H. (2005). Opinion: NK3 receptor antagonists: the next generation of antipsychotics? Nat Rev Drug Discov 4:967–975.
   PubMed Web of Science ®Google Scholar
• US Food and Drug Administration. Draft Guidance for Industry: Drug Interaction Studies - Study Design, Data Analysis and Implications for Dosing and Labeling, 2006. Available at: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/ Guidances/ucm072101.pdf. Accessed March 28, 2010.
   Google Scholar
• Wang H, Faucette S, Moore R, Sueyoshi T, Negishi M, LeCluyse E. (2004). Human constitutive androstane receptor mediates induction of CYP2B6 gene expression by phenytoin. J Biol Chem 279:29295–29301.
   PubMed Web of Science ®Google Scholar
• Wang YH, Jones DR, Hall SD. (2005). Differential mechanism-based inhibition of CYP3A4 and CYP3A5 by verapamil. Drug Metab Dispos 33:664–671.
   PubMed Web of Science ®Google Scholar
• Wang B, Wang J, Huang SQ, Su HH, Zhou SF. (2009). Genetic polymorphism of the human cytochrome P450 2C9 gene and its clinical significance. Curr Drug Metab 10:781–834.
   PubMed Web of Science ®Google Scholar
• Westlind-Johnsson A, Malmebo S, Johansson A, Otter C, Andersson TB, Johansson I, Edwards RJ, Boobis AR, Ingelman-Sundberg M. (2003). Comparative analysis of CYP3A expression in human liver suggests only a minor role for CYP3A5 in drug metabolism. Drug Metab Dispos 31:755–761.
   PubMed Web of Science ®Google Scholar
• Wu LH, Vartanian MA, Oxender DL, Chung FZ. (1994). Identification of methionine134 and alanine146 in the second transmembrane segment of the human tachykinin NK3 receptor as reduces involved in species-selective binding to SR 48968. Biochem Biophys Res Commun 198:961–966.
   PubMedGoogle Scholar